Physiologically-based pharmacokinetic analysis of grepafloxacin

Yukiko Nakajima, Kenji Hattori, Machiko Shinsei, Noriko Matsunaga, Hisashi Iizasa, Hiroyuki Sasabe, Hitoshi Akiyama, Gohachiro Miyamoto, Emi Nakashima

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Grepafloxacin (GPFX) is a synthetic new quinolone antimicrobial agent that possesses an extensive tissue distribution and exhibits a strong antibacterial activity in vivo. In this study, the tissue distribution characteristics of GPFX were examined using tissue concentration-time profiles following intravenous administration to rats. Subsequently, the pharmacokinetics of GPFX were analyzed based on the physiological pharmacokinetic model. The tissue-to-plasma partition coefficients (K(p)) of GPFX in rats were high in all tissues except brain. A pharmacokinetic model for rabbits, monkeys and dogs was constructed using the tissue-to-plasma free concentration ratio (K(p,f)) of GPFX in rats to simulate the GPFX concentration-time profile in plasma following intravenous administration of GPFX to each animal. The calculation-derived concentrations correlated well with the experimentally-derived data, suggesting that there are no interspecies differences in the high tissue distribution characteristics of GPFX. The clearance rates of GPFX in humans were predicted from the pharmacokinetic parameters of rats, rabbits, monkeys and dogs by an animal scale-up method and a pharmacokinetic model for humans was constructed. The GPFX concentration-time profiles in plasma, following oral administration of GPFX to humans, were predicted within 0.5 - 1.0 h of mean absorption time and the calculation-derived results were in good agreement with the experimental data. Thus, it is suggested that the concentration-time profile in plasma and all human organs can be predicted from the pharmacokinetic data of animals.

Original languageEnglish
Pages (from-to)1077-1083
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume23
Issue number9
Publication statusPublished - 2000

Fingerprint

Pharmacokinetics
Tissue Distribution
Intravenous Administration
Haplorhini
grepafloxacin
Dogs
Rabbits
Quinolones
Anti-Infective Agents
Oral Administration
Brain

Keywords

  • Animal scale-up
  • Grepafloxacin
  • Physiological pharmacokinetic model
  • Tissue distribution

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nakajima, Y., Hattori, K., Shinsei, M., Matsunaga, N., Iizasa, H., Sasabe, H., ... Nakashima, E. (2000). Physiologically-based pharmacokinetic analysis of grepafloxacin. Biological and Pharmaceutical Bulletin, 23(9), 1077-1083.

Physiologically-based pharmacokinetic analysis of grepafloxacin. / Nakajima, Yukiko; Hattori, Kenji; Shinsei, Machiko; Matsunaga, Noriko; Iizasa, Hisashi; Sasabe, Hiroyuki; Akiyama, Hitoshi; Miyamoto, Gohachiro; Nakashima, Emi.

In: Biological and Pharmaceutical Bulletin, Vol. 23, No. 9, 2000, p. 1077-1083.

Research output: Contribution to journalArticle

Nakajima, Y, Hattori, K, Shinsei, M, Matsunaga, N, Iizasa, H, Sasabe, H, Akiyama, H, Miyamoto, G & Nakashima, E 2000, 'Physiologically-based pharmacokinetic analysis of grepafloxacin', Biological and Pharmaceutical Bulletin, vol. 23, no. 9, pp. 1077-1083.
Nakajima Y, Hattori K, Shinsei M, Matsunaga N, Iizasa H, Sasabe H et al. Physiologically-based pharmacokinetic analysis of grepafloxacin. Biological and Pharmaceutical Bulletin. 2000;23(9):1077-1083.
Nakajima, Yukiko ; Hattori, Kenji ; Shinsei, Machiko ; Matsunaga, Noriko ; Iizasa, Hisashi ; Sasabe, Hiroyuki ; Akiyama, Hitoshi ; Miyamoto, Gohachiro ; Nakashima, Emi. / Physiologically-based pharmacokinetic analysis of grepafloxacin. In: Biological and Pharmaceutical Bulletin. 2000 ; Vol. 23, No. 9. pp. 1077-1083.
@article{1a61ca6ac2ef44bf8e87ae98112a9dd7,
title = "Physiologically-based pharmacokinetic analysis of grepafloxacin",
abstract = "Grepafloxacin (GPFX) is a synthetic new quinolone antimicrobial agent that possesses an extensive tissue distribution and exhibits a strong antibacterial activity in vivo. In this study, the tissue distribution characteristics of GPFX were examined using tissue concentration-time profiles following intravenous administration to rats. Subsequently, the pharmacokinetics of GPFX were analyzed based on the physiological pharmacokinetic model. The tissue-to-plasma partition coefficients (K(p)) of GPFX in rats were high in all tissues except brain. A pharmacokinetic model for rabbits, monkeys and dogs was constructed using the tissue-to-plasma free concentration ratio (K(p,f)) of GPFX in rats to simulate the GPFX concentration-time profile in plasma following intravenous administration of GPFX to each animal. The calculation-derived concentrations correlated well with the experimentally-derived data, suggesting that there are no interspecies differences in the high tissue distribution characteristics of GPFX. The clearance rates of GPFX in humans were predicted from the pharmacokinetic parameters of rats, rabbits, monkeys and dogs by an animal scale-up method and a pharmacokinetic model for humans was constructed. The GPFX concentration-time profiles in plasma, following oral administration of GPFX to humans, were predicted within 0.5 - 1.0 h of mean absorption time and the calculation-derived results were in good agreement with the experimental data. Thus, it is suggested that the concentration-time profile in plasma and all human organs can be predicted from the pharmacokinetic data of animals.",
keywords = "Animal scale-up, Grepafloxacin, Physiological pharmacokinetic model, Tissue distribution",
author = "Yukiko Nakajima and Kenji Hattori and Machiko Shinsei and Noriko Matsunaga and Hisashi Iizasa and Hiroyuki Sasabe and Hitoshi Akiyama and Gohachiro Miyamoto and Emi Nakashima",
year = "2000",
language = "English",
volume = "23",
pages = "1077--1083",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "9",

}

TY - JOUR

T1 - Physiologically-based pharmacokinetic analysis of grepafloxacin

AU - Nakajima, Yukiko

AU - Hattori, Kenji

AU - Shinsei, Machiko

AU - Matsunaga, Noriko

AU - Iizasa, Hisashi

AU - Sasabe, Hiroyuki

AU - Akiyama, Hitoshi

AU - Miyamoto, Gohachiro

AU - Nakashima, Emi

PY - 2000

Y1 - 2000

N2 - Grepafloxacin (GPFX) is a synthetic new quinolone antimicrobial agent that possesses an extensive tissue distribution and exhibits a strong antibacterial activity in vivo. In this study, the tissue distribution characteristics of GPFX were examined using tissue concentration-time profiles following intravenous administration to rats. Subsequently, the pharmacokinetics of GPFX were analyzed based on the physiological pharmacokinetic model. The tissue-to-plasma partition coefficients (K(p)) of GPFX in rats were high in all tissues except brain. A pharmacokinetic model for rabbits, monkeys and dogs was constructed using the tissue-to-plasma free concentration ratio (K(p,f)) of GPFX in rats to simulate the GPFX concentration-time profile in plasma following intravenous administration of GPFX to each animal. The calculation-derived concentrations correlated well with the experimentally-derived data, suggesting that there are no interspecies differences in the high tissue distribution characteristics of GPFX. The clearance rates of GPFX in humans were predicted from the pharmacokinetic parameters of rats, rabbits, monkeys and dogs by an animal scale-up method and a pharmacokinetic model for humans was constructed. The GPFX concentration-time profiles in plasma, following oral administration of GPFX to humans, were predicted within 0.5 - 1.0 h of mean absorption time and the calculation-derived results were in good agreement with the experimental data. Thus, it is suggested that the concentration-time profile in plasma and all human organs can be predicted from the pharmacokinetic data of animals.

AB - Grepafloxacin (GPFX) is a synthetic new quinolone antimicrobial agent that possesses an extensive tissue distribution and exhibits a strong antibacterial activity in vivo. In this study, the tissue distribution characteristics of GPFX were examined using tissue concentration-time profiles following intravenous administration to rats. Subsequently, the pharmacokinetics of GPFX were analyzed based on the physiological pharmacokinetic model. The tissue-to-plasma partition coefficients (K(p)) of GPFX in rats were high in all tissues except brain. A pharmacokinetic model for rabbits, monkeys and dogs was constructed using the tissue-to-plasma free concentration ratio (K(p,f)) of GPFX in rats to simulate the GPFX concentration-time profile in plasma following intravenous administration of GPFX to each animal. The calculation-derived concentrations correlated well with the experimentally-derived data, suggesting that there are no interspecies differences in the high tissue distribution characteristics of GPFX. The clearance rates of GPFX in humans were predicted from the pharmacokinetic parameters of rats, rabbits, monkeys and dogs by an animal scale-up method and a pharmacokinetic model for humans was constructed. The GPFX concentration-time profiles in plasma, following oral administration of GPFX to humans, were predicted within 0.5 - 1.0 h of mean absorption time and the calculation-derived results were in good agreement with the experimental data. Thus, it is suggested that the concentration-time profile in plasma and all human organs can be predicted from the pharmacokinetic data of animals.

KW - Animal scale-up

KW - Grepafloxacin

KW - Physiological pharmacokinetic model

KW - Tissue distribution

UR - http://www.scopus.com/inward/record.url?scp=0033774028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033774028&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1077

EP - 1083

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 9

ER -